Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

Else Marie Agger; Ida Rosenkrands; Anja Weinreich Olsen; Graham Hatch; Ann Williams; Constantia Kritsch; Karen Lingnau; Alexander von Gabain; Claire Swetman Andersen; Karen Smith Korsholm; Peter Andersen

doi:10.1016/j.vaccine.2006.03.072

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

Else Marie Agger^*
, Ida Rosenkrands
, Anja Weinreich Olsen
, Graham Hatch
, Ann Williams
, Constantia Kritsch
, Karen Lingnau
, Alexander von Gabain
, Claire Swetman Andersen
, Karen Smith Korsholm
, Peter Andersen

^*Corresponding author for this work

Biological Investigations Group

Research output: Contribution to journal › Article › peer-review

120 Citations (Scopus)

Abstract

In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL₅KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-γ secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.

Original language	English
Pages (from-to)	5452-5460
Number of pages	9
Journal	Vaccine
Volume	24
Issue number	26
DOIs	https://doi.org/10.1016/j.vaccine.2006.03.072
Publication status	Published - 29 Jun 2006

Bibliographical note

Funding Information:
This study was funded by the European Commision (contract no. LSHP-CT-2003-503367). We are grateful that the project was supported by the Austrian Federal Ministry for Economy and Labour as well as by the City of Vienna (WWFF).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adjuvant
Tuberculosis
Vaccine

Access to Document

10.1016/j.vaccine.2006.03.072

Cite this

@article{d2d00a7e4cb2423b95fd7646d5007669,

title = "Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31",

abstract = "In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL5KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-γ secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.",

keywords = "Adjuvant, Tuberculosis, Vaccine",

author = "Agger, \{Else Marie\} and Ida Rosenkrands and Olsen, \{Anja Weinreich\} and Graham Hatch and Ann Williams and Constantia Kritsch and Karen Lingnau and \{von Gabain\}, Alexander and Andersen, \{Claire Swetman\} and Korsholm, \{Karen Smith\} and Peter Andersen",

note = "Funding Information: This study was funded by the European Commision (contract no. LSHP-CT-2003-503367). We are grateful that the project was supported by the Austrian Federal Ministry for Economy and Labour as well as by the City of Vienna (WWFF). ",

year = "2006",

month = jun,

day = "29",

doi = "10.1016/j.vaccine.2006.03.072",

language = "English",

volume = "24",

pages = "5452--5460",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "26",

}

TY - JOUR

T1 - Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

AU - Agger, Else Marie

AU - Rosenkrands, Ida

AU - Olsen, Anja Weinreich

AU - Hatch, Graham

AU - Williams, Ann

AU - Kritsch, Constantia

AU - Lingnau, Karen

AU - von Gabain, Alexander

AU - Andersen, Claire Swetman

AU - Korsholm, Karen Smith

AU - Andersen, Peter

N1 - Funding Information: This study was funded by the European Commision (contract no. LSHP-CT-2003-503367). We are grateful that the project was supported by the Austrian Federal Ministry for Economy and Labour as well as by the City of Vienna (WWFF).

PY - 2006/6/29

Y1 - 2006/6/29

N2 - In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL5KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-γ secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.

AB - In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL5KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-γ secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.

KW - Adjuvant

KW - Tuberculosis

KW - Vaccine

UR - https://www.scopus.com/pages/publications/33744815623

U2 - 10.1016/j.vaccine.2006.03.072

DO - 10.1016/j.vaccine.2006.03.072

M3 - Article

C2 - 16675077

AN - SCOPUS:33744815623

SN - 0264-410X

VL - 24

SP - 5452

EP - 5460

JO - Vaccine

JF - Vaccine

IS - 26

ER -

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this